Max Chat
Company Analysis G1 Therapeutics
1. Summary
Advantages
- Price (1.61 $) is less than fair price (7.76 $)
- The stock's return over the last year (0.2805%) is higher than the sector average (-2.01%).
Disadvantages
- Dividends (0%) are below the sector average (0.5261%).
- Current debt level 43.47% has increased over 5 years from 3.58%.
- The company's current efficiency (ROE=-135.55%) is lower than the sector average (ROE=14.17%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
| G1 Therapeutics | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -20.5% | 3.2% |
| 90 days | 0% | -0.7% | 13% |
| 1 year | 0.3% | -2% | 12.8% |
GTHX vs Sector: G1 Therapeutics has outperformed the "Healthcare" sector by 2.29% over the past year.
GTHX vs Market: G1 Therapeutics has significantly underperformed the market by -12.56% over the past year.
Stable price: GTHX is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: GTHX with weekly volatility of 0.0054% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (1.61 $) is lower than the fair price (7.76 $).
Price significantly below the fair price: The current price (1.61 $) is 382% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (63.23).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (89.86).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (4.36) is lower than that of the sector as a whole (18.83).
P/BV vs Market: The company's P/BV (4.36) is lower than that of the market as a whole (9.35).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.87) is lower than that of the sector as a whole (32.67).
P/S vs Market: The company's P/S indicator (1.87) is lower than that of the market as a whole (10.1).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-4.59) is lower than that of the sector as a whole (274.42).
EV/Ebitda vs Market: The company's EV/Ebitda (-4.59) is lower than that of the market as a whole (50.71).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -10.34% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-10.34%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-15.75%).
5.4. ROE
ROE vs Sector: The company's ROE (-135.55%) is lower than that of the sector as a whole (14.17%).
ROE vs Market: The company's ROE (-135.55%) is lower than that of the market as a whole (11.64%).
5.5. ROA
ROA vs Sector: The company's ROA (-39.47%) is lower than that of the sector as a whole (1.18%).
ROA vs Market: The company's ROA (-39.47%) is lower than that of the market as a whole (6.88%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-71.97%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-71.97%) is lower than that of the market as a whole (11%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5261%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
